Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A Single Agent For The Treatment Of Waldenstrom's Macroglobulinemia
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A Single Agent For The Treatment Of Waldenstrom's Macroglobulinemia
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A Single Agent For The Treatment Of Waldenstrom's Macroglobulinemia
Submitted by
admin
on January 30, 2010 - 12:14pm
Source:
Medical News Today
News Tags:
Keryx
Waldenstrom's Macroglobulinemia
Headline:
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A Single Agent For The Treatment Of Waldenstrom's Macroglobulinemia
Do Not Allow Advertisers to Use My Personal information
